DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
van Glabbeke M, Hogendoorn PCW, Mouridsen H. et al.
Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma: what should be the target? A retrospective study of the EORTC Soft Tissue and Bone Sarcoma (STBSG) database.
Proc Am Soc Clin Oncol 2001; 20: 354a(abstr)
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.